大株红景天注射液联合常规治疗对急性心衰患者血清PAB、BNP和hs-CRP水平的影响分析

Effects of the Dazhu Hongjingtian injection plus conventional therapy on serum PAB, BNP and hs-CRP levels in patients with acute heart failure

目的:分析大株红景天注射液联合常规治疗对急性心力衰竭(简称急性心衰)患者血清前白蛋白(Prealbumin,PAB)、B型脑钠肽(B-type Brain Natriuretic Peptide,BNP)和高敏C-反应蛋白(High-sensitivity C-reactive Protein,hs-CRP)水平的影响。方法:将我院收治的急性心力衰竭患者64例随机分为对照组与治疗组各32例,对照组采用常规西医治疗,治疗组在对照组基础上应用大株红景天注射液进行联合治疗,比较两组临床疗效、心脏彩超指标水平及血清PAB、BNP、hs-CRP水平、心衰再发次数、不良反应差异。结果:治疗后,治疗组临床治疗总有效率显著高于对照组(P<0.05);治疗后心脏彩超指标比较,治疗组左心室射血分数(Left Ventricular Ejection Fraction,LVEF)水平显著升高(P<0.05),左心室舒张末期直径(Left Ventricular End-Diastolic Diameter,LVEDD)、左心室收缩末期直径(Left Ventricular End-Systolic Diameter,LVESD)水平显著降低(P<0.05),且治疗组升高或降低幅度更大(P<0.05);治疗后,两组血清PAB水平显著升高(P<0.05),BNP、hs-CRP水平显著降低(P<0.05),且治疗组升高或降低幅度更大(P<0.05);治疗20 d内,治疗组再次心衰次数显著少于对照组(P<0.05),两组均未见其他严重药物不良反应。结论:大株红景天注射液联合常规治疗有利于改善急性心衰患者心功能与血清血清PAB、BNP和hs-CRP水平,安全性高,值得临床推广。

Objective:To analyze the effects of the Dazhu Hongjingtian injection(大株红景天注射液)plus conventional therapy on serum PAB,BNP and hs-CRP levels in patients with acute heart failure.Methods:64 patients were randomly divided into the control group and treatment group,32 cases in each.The control group was treated with conventional western medicine;the treatment group was treated with the Dazhu Hongjingtian injection more.The clinical efficacy,cardiac color ultrasound indexes and serum PAB,BNP and hs-CRP levels,frequency of recurrent heart failure,and adverse reactions were compared between the two groups.Results:After treatment,the total efficiency in the treatment group was significantly higher than that in the control group(P<0.05).The level LVEF in treatment group was significantly increased(P<0.05);and the levels of LVEDD and LVESD were significantly decreased(P<0.05);and the increases or decreases were greater in the treatment group(P<0.05).After treatment,the serum PAB levels in two groups were significantly elevated(P<0.05);and the levels of BNP and hs-CRP were significantly decreased(P<0.05);and the increases or decreases were greater in the treatment group(P<0.05).Within 20 days of treatment,the frequency of recurrent heart failure in the treatment group was significantly less than that in the control group(P<0.05).There was no serious adverse drug reactions in two group.Conclusions:The Dazhu Hongjingtian injection plus conventional therapy can improve the cardiac function and serum PAB,BNP and hs-CRP levels in patients with acute heart failure,is safety and worthy of clinical promotion.